Literature DB >> 13590382

Multiple sclerosis and allied diseases in Japan; clinical characteristics.

S OKINAKA, T TSUBAKI, Y KUROIWA, Y TOYOKURA, Y IMAMURA.   

Abstract

Entities:  

Keywords:  MULTIPLE SCLEROSIS/epidemiology

Mesh：

Substances：

Year:  1958        PMID： 13590382     DOI： 10.1212/wnl.8.10.756

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Comparative epidemiological studies of multiple sclerosis in South Africa and Japan.

Authors:  A V Bird; E Satoyoshi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-09       Impact factor: 10.154

Review 2.  Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

Authors:  Axel Petzold
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

3.  Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody.

Authors:  Masami Tanaka; Keiko Tanaka; Mika Komori; Takahiko Saida
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

Review 4.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

5.  Clinical studies of multiple sclerosis in Japan. Multiple sclerosis starting with retrobulbar neuritis.

Authors:  H Shibasaki; Y Kuroda; H Iwashita; Y Kuroiwa
Journal:  J Neurol       Date:  1974       Impact factor: 4.849

6.  An Autopsy Confirmed Neuromyelitis Optica Spectrum Disorder with Extensive Brain White Matter Lesion and Optic Neuritis but Intact Spinal Cord, Clinically Mimicking a Secondary Progressive Multiple Sclerosis-like Course.

Authors:  Fumika Azuma; Kazuya Nokura; Tetsuharu Kako; Mari Yoshida; Shinsui Tatsumi
Journal:  Intern Med       Date:  2021-10-12       Impact factor: 1.282
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.